GlassScriptPhysician profile
Laura M Perrin
NPI 1720561715
$2,287.11
in general payments reported to CMS, 2019-2025
19 companies · $766 in 2025
The $766 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $332 · 2023: $183 · 2024: $1,007 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,955.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $380.66 | 2024-2025 | Infuse, Biotrue One Day |
| Vifor Pharma, INC. | $277.96 | 2022-2025 | Veltassa |
| Ardelyx, INC. | $255.96 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Amgen INC. | $245.69 | 2024-2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $212.05 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.39 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $169.04 | 2022-2024 | Lokelma, Farxiga |
| Edwards Lifesciences Corporation | $145.32 | 2023 | Pascal |
| Travere Therapeutics, INC. | $109.69 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $103.47 | 2022-2025 | Velphoro, Velphoro |
| Otsuka America Pharmaceutical, INC. | $49.93 | 2025 | Jynarque |
| Novo Nordisk INC | $31.29 | 2025 | Ozempic, Rybelsus, Wegovy |
| Johnson & Johnson Vision Care, INC. | $18.11 | 2024 | |
| Glaxosmithkline, LLC. | $17.55 | 2025 | Arexvy, Shingrix |
| Genzyme Corporation | $16.61 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $15.99 | 2024 | Auryxia, Vafseo |
| Scpharmaceuticals INC. | $15.96 | 2025 | |
| Aurinia Pharma U.S., INC. | $13.17 | 2022 | |
| Opko Pharmaceuticals, LLC | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Perrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.